# Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

> **NCT03839446** · PHASE2 · COMPLETED · sponsor: **Robert Redner, MD** · enrollment: 16 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** mitoxantrone + etoposide + gemtuzumab ozogamicin

## Key facts

- **NCT ID:** NCT03839446
- **Lead sponsor:** Robert Redner, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-28
- **Primary completion:** 2023-02-02
- **Final completion:** 2024-12-22
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03839446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03839446, "Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03839446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*